跳到正文
原文
STAT Pharma 医药频道· Elaine Chen·· 2 天前AI 评分33

Sellas 生物癌免疫疗法降低急性髓系白血病患者死亡风险41%

STAT+: Flagship opens biotech-creation outpost in the U.K.

AI 导读

Sellas 生物公司的一种实验性药物在治疗晚期急性髓系白血病患者时,将死亡风险降低了41%,相比标准治疗有显著改善。

正文

Scientists unveil details of brain gene therapy death, a potential blockbuster from Roche, and more biotech news

Adobe

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. We’ve got a lot of news to get into today, including some big developments in oncology.

The need-to-know this morning

Sellas’ blood cancer immunotherapy cut risk of death

An experimental drug from Sellas Life Sciences reduced the risk of death by 41% compared to standard treatment for patients with an advanced stage of acute myeloid leukemia, the company said this morning.

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

  1. National Biotech Reporter

    Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.

来源:STAT Pharma 医药频道 · statnews.com